Sarepta Therapeutics Inc. (SRPT) and Coherus BioSciences Inc. (NASDAQ:CHRS) Comparison side by side

Both Sarepta Therapeutics Inc. (NASDAQ:SRPT) and Coherus BioSciences Inc. (NASDAQ:CHRS) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sarepta Therapeutics Inc. 273.90M 32.69 245.02M -3.75 0.00
Coherus BioSciences Inc. N/A 0.00 195.81M -3.13 0.00

Table 1 demonstrates Sarepta Therapeutics Inc. and Coherus BioSciences Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 provides the return on assets, net margins and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
Sarepta Therapeutics Inc. -89.46% -33.7% -19.5%
Coherus BioSciences Inc. 0.00% -741.7% -126.2%

Volatility & Risk

Sarepta Therapeutics Inc. has a beta of 1.84 and its 84.00% more volatile than Standard and Poor’s 500. Coherus BioSciences Inc.’s 265.00% more volatile than Standard and Poor’s 500 which is a result of the 3.65 beta.

Liquidity

Sarepta Therapeutics Inc. has a Current Ratio of 8.8 and a Quick Ratio of 7.8. Competitively, Coherus BioSciences Inc.’s Current Ratio is 5.3 and has 5.3 Quick Ratio. Sarepta Therapeutics Inc.’s better ability to pay short and long-term obligations than Coherus BioSciences Inc.

Analyst Recommendations

Sarepta Therapeutics Inc. and Coherus BioSciences Inc. Recommendations and Ratings are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Sarepta Therapeutics Inc. 0 0 5 3.00
Coherus BioSciences Inc. 0 0 1 3.00

Sarepta Therapeutics Inc. has a consensus target price of $190.4, and a 49.92% upside potential. Competitively Coherus BioSciences Inc. has a consensus target price of $28, with potential upside of 103.64%. Based on the results given earlier, Coherus BioSciences Inc. is looking more favorable than Sarepta Therapeutics Inc., analysts belief.

Institutional & Insider Ownership

Roughly 93.3% of Sarepta Therapeutics Inc. shares are owned by institutional investors while 95.7% of Coherus BioSciences Inc. are owned by institutional investors. About 5.7% of Sarepta Therapeutics Inc.’s share are owned by insiders. Competitively, Coherus BioSciences Inc. has 0.1% of it’s share owned by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Sarepta Therapeutics Inc. -5.15% -14.76% -12.41% 25.28% 128.59% 120.7%
Coherus BioSciences Inc. -10.04% -20.27% -44.41% -37.81% 17.75% 13.07%

For the past year Sarepta Therapeutics Inc. was more bullish than Coherus BioSciences Inc.

Summary

Sarepta Therapeutics Inc. beats Coherus BioSciences Inc. on 6 of the 10 factors.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD. The company has a strategic alliance with Nationwide Children's Hospital for the advancement of microdystrophin gene therapy program under the research and option agreement, as well as Galgt2 gene therapy program under the license agreement; Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD under the research collaboration agreement; and CharleyÂ’s Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies under the research agreement. It also has a license agreement with the University of Western Australia for treatment of DMD by inducing the skipping of certain exons; collaboration and license agreement with Summit (Oxford) Ltd. for the development of ezutromid, an utrophin modulator which is in phase II clinical trials for the treatment of DMD; and a gene therapy research collaboration with Genethon to develop treatments for Duchenne muscular dystrophy. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company’s product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, Crohn’s Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.